View clinical trials related to T2DM (Type 2 Diabetes Mellitus).
Filter by:The goal of this clinical study is to evaluate the efficacy and safety of berberine ursodeoxycholate (HTD1801) compared to dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone.
The goal of this clinical study is to evaluate the efficacy and safety of Berberine Ursodeoxycholate (HTD1801) compared to placebo in patients with type 2 diabetes, inadequately controlled with diet and exercise alone.
The goal of this observational study is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are: - major adverse cardiovascular events within 48 months of the trial duration - microvascular events within 48 months of the trial duration
The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with type 2 diabetes mellitus. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.
The subjects, having voluntarily agreed to participate in the clinical trial and provided informed consent, will undergo screening tests. During Visit 1 (Screening), subjects meeting the inclusion/exclusion criteria will go through an 8-week stabilization period. At Visit 1-1, central laboratory tests will be conducted. If the test results meet the criteria for Visit 2 (Enrollment Visit), the subject will be eligible to participate in the clinical trial. The subjects will receive the investigational drug (DWP16001 0.3 mg) once a day for 52 weeks. They will visit the clinical trial site at weeks 8, 16, 24, 38, and 52 for safety and efficacy assessments during the 52-week treatment period.
The purpose of this project is to evaluate the effectiveness of a virtual diabetes group visits on patients with type 2 diabetes mellitus (T2DM).
T2DM patient will be recruited from endocrine OPD 1. Clinical History and Examination: 1. General Physical Examination: - Height (cm) - weight (kg) - BMI (kg/m2) - Blood Pressure (mmHg) 2. Anthropometry: Circumferences and skinfold thickness will be recorded for the patients in the following manner. Circumferences: - Waist circumference (cm) - Hip circumference (cm) - Mid-arm circumference (cm) - Mid-thigh circumference (cm) 3. Skin fold thickness: Skin fold thickness will be measured by using (LANGE skin fold calipers) (to nearest of 1 mm) at the following sites - Biceps (mm) - Triceps (mm) - Thigh (mm) - Calf (mm) - Sub scapular (mm) - Supra-iliac (mm) - Anterior axillary fold. (mm) 2. Biochemical Test: The biochemical analysis will be done using ELISA kit or commercially available kits - Blood glucose (mg/dL) - HbA1c (%) - Serum insulin (μIU/mL) - Total Cholestrol (mg/dl) - Triglyceride (mg/dl) - Fructosamine (umol/L) - Adiponectin (µg/ml) -- HOMA-IR 3. Body Composition Analysis (TANITA)
To evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of single dose of HSK7653 tablets in healthy adult subjects, and to identify the metabolites of HSK7653 in healthy adult subjects
This is a single-center, randomized, double-blind, placebo-controlled, escalating single-dose and multiple-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HEC88473 injection in healthy subjects, obese subjects and subjects with type 2 diabetes mellitus (T2DM).
This multicenter, randomized, open-label, controlled study will assess the efficacy of the SGLT2 inhibitor tofogliflozin on Urine Albumin-to-Creatinine Ratio (UACR) compared to metformin in patients with type 2 diabetes with chronic kidney disease (CKD).